Skip to content

Precision Cardiovascular Disease

Precision Cardiovascular Disease - Precision-CVD

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00040672
Enrollment
2000
Registered
2026-06-26
Start date
2026-01-13
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease, coronary microvascular dysfunction

Interventions

Group 1: Adult patients with a cardiovascular risk profile and a wide spectrum of comorbidities undergoing elective cardiac catheterization or an electrophysiological study.

Sponsors

Friede Springer Cardiovascular Reseach Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: invasive cardiac diagnostics Consent to participate

Exclusion criteria

Exclusion criteria: consent withdrawn, inability to consent

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the occurrence of MACE (major adverse cardiovascular events): stroke, myocardial infarction, and death. Follow-up of the study participants is planned for 10 years after enrollment.

Secondary

MeasureTime frame
Secondary endpoints include, among others: - Coronary function measurements - Patient characterization using questionnaires to assess relevant risk factors - Standard laboratory parameters (incl. blood count, lipid parameters, renal retention markers, liver enzymes, natriuretic peptides, troponin, C-reactive protein, glucose metabolism) - Blood metabolites (mass spectrometry) - Proteome analyses (Olink, multiplex ELISA) - fecal analysis of gut microbial composition and metabolites - Genotyping, genome sequencing - Immune cell function in peripheral blood - Coagulation parameters and platelet function measurements - Urine metabolites

Countries

Germany

Contacts

Public ContactMarco Witkowski

Friede Springer Cardiovascular Prevention Center @Charite Universitätsmedizin Berlin

marco.witkowski@dhzc-charite.de+49 30 450 613839

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026